Nabriva Therapeutics Plc (NBRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nabriva Therapeutics Plc (NBRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137589D
  • |
  • Pages: 76
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company's product candidate includes lefamulin, a pleuromutilin antibiotic, being developed in both intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia. Its other pipeline products comprise BC-7013 for the topical treatment of a variety of gram-positive infections including uncomplicated skin and skin structure infections; and Contepo to treat urinary tract infections. It partners with pharmaceutical and biotechnology companies. It has operational presence in Austria and the US. Nabriva is headquartered in Dublin, Ireland.

Nabriva Therapeutics Plc (NBRV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Nabriva Therapeutics Raises USD120 Million in Series B Financing 11

Private Equity 13

Ally Bridge Invests in Nabriva Therapeutics 13

Licensing Agreements 14

Sinovant Sciences Enters into Licensing Agreement with Nabriva 14

Equity Offering 15

Nabriva Therapeutics Raises USD50 Million in Public Offering of Shares 15

Nabriva Therapeutics Raises USD80 Million in Public Offering of Shares 17

Nabriva Therapeutics Raises USD25 Million in Rights Offering of Shares 19

Nabriva Therapeutics Raises USD106.1 Million in IPO of ADS 21

Acquisition 23

Nabriva Therapeutics Acquires Zavante Therapeutics 23

Nabriva Therapeutics Plc-Key Competitors 24

Nabriva Therapeutics Plc-Key Employees 25

Nabriva Therapeutics Plc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Aug 09, 2018: Nabriva Therapeutics reports second quarter 2018 financial results and recent corporate highlights 27

May 08, 2018: Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights 29

Mar 16, 2018: Nabriva Therapeutics Announces 2017 Financial Results 30

Nov 09, 2017: Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights 32

Aug 07, 2017: Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 34

May 10, 2017: Nabriva Therapeutics Reports First Quarter 2017 Financial Results 36

Mar 24, 2017: Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results 37

Corporate Communications 38

Mar 21, 2018: Nabriva Therapeutics Names Jennifer Schranz As Chief Medical Officer 38

Dec 13, 2017: Nabriva Therapeutics Added to NASDAQ Biotechnology Index 39

Aug 31, 2017: Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D. 40

Jul 11, 2017: Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer 41

Jun 26, 2017: Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board 42

Product News 43

10/04/2017: Zavante Therapeutics Presents Additional Clinical And Microbiologic Data From ZOLYD Phase 2/3 Trial At ID Week 2017 43

09/28/2017: Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017 45

09/20/2017: Zavante Therapeutics To Present ZOLYD Data From Pivotal ZEUS Study At ID Week 2017 47

06/05/2017: Zavante Therapeutics Reports ZOLYD Broad Spectrum Activity and Synergy With Multiple Antibiotics; in vitro Studies Presented at ASM Microbe 2017 Meeting 49

04/05/2017: Zavante Therapeutics' ZOLYD Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections 50

Clinical Trials 52

May 31, 2018: Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe 52

May 29, 2018: Nabriva Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference 54

May 21, 2018: Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia 55

May 21, 2018: Zavante Therapeutics to Present Fosfomycin For Injection Data At ASM Microbe 2018 Meeting 57

Apr 13, 2018: Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia 59

Dec 04, 2017: Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults 61

Oct 25, 2017: Nabriva Therapeutics to Present at the Stifel 2017 Healthcare Conference 62

Sep 20, 2017: Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference 63

Sep 18, 2017: Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia 64

Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 66

Jun 05, 2017: Zavante Therapeutics Presents Positive Results From NIH-Sponsored ZOLYD Phase 1 Trial At ASM Microbe 2017 Meeting 67

Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin 68

May 17, 2017: Zavante Therapeutics to Present ZOLYD Data at ASM Microbe 2017 Meeting 69

Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin 71

Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia 73

Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia 74

Jan 19, 2017: Zavante Therapeutics Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01 (fosfomycin for injection) For The Treatment Of Complicated Urinary Tract Infections 75

Appendix 76

Methodology 76

About GlobalData 76

Contact Us 76

Disclaimer 76

List of Figures

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nabriva Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nabriva Therapeutics Raises USD120 Million in Series B Financing 11

Ally Bridge Invests in Nabriva Therapeutics 13

Sinovant Sciences Enters into Licensing Agreement with Nabriva 14

Nabriva Therapeutics Raises USD50 Million in Public Offering of Shares 15

Nabriva Therapeutics Raises USD80 Million in Public Offering of Shares 17

Nabriva Therapeutics Raises USD25 Million in Rights Offering of Shares 19

Nabriva Therapeutics Raises USD106.1 Million in IPO of ADS 21

Nabriva Therapeutics Acquires Zavante Therapeutics 23

Nabriva Therapeutics Plc, Key Competitors 24

Nabriva Therapeutics Plc, Key Employees 25

Nabriva Therapeutics Plc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Nabriva Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com